Can molotinib/mometinib be purchased in China?

Momelotinib is a new drug used to treat myelofibrosis (MF). It has gained certain recognition internationally and is especially suitable for the treatment of moderate or high-risk myelofibrosis in adults with anemia, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia). However, there are still certain restrictions on the availability of the drug in the Chinese market.

The original drug of molotinib has not yet been officially launched in China. This means that patients cannot yet purchase the drug through formal channels in domestic hospitals or pharmacies. This situation occurs, on the one hand, because the drug registration and approval process is complex and time-consuming, and on the other hand, it is also related to market demand and production costs. As a result, patients often face drug shortages when seeking treatment, resulting in limited treatment options.

Although the original drug is not yet on the market, the first generic version of molotinib has appeared on the market. These generic drugs are usually developed by some domestic and foreign pharmaceutical companies and obtained certification through legal channels. Take the 100mg*30-tablet generic drug produced by Lucius Pharmaceuticals in Laos as an example. Its price is relatively low, about more than 2,000 yuan per box, which is undoubtedly a more economical choice for many patients. Although the ingredients and efficacy of generic drugs are close to those of the original drugs, patients still need to follow their doctors' recommendations when using them and conduct relevant health monitoring regularly to ensure safe and effective treatment.

In addition, as molotinib is an emerging drug, its recognition in the medical system needs to be improved. Although some hospitals have begun to pay attention to and understand this drug, there are still large differences in clinical application and doctors' prescription habits.